Entero Therapeutics Inc
ENTO2.990USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.62MMarket Cap
LossP/E TTM
More Details of Entero Therapeutics Inc Company
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. It is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP. Its subsidiary, Grid AI Corp., is an artificial intelligence (AI)-driven, grid-edge software and device orchestration platform.
Entero Therapeutics Inc Info
Ticker SymbolENTO
Company nameGridAI Technologies Corp
IPO dateOct 11, 2016
CEOSawyer (Jason)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endOct 11
Address777 Yamato Road
CityBOCA RATON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33431
Phone15615897020
Websitehttps://enterothera.com/
Ticker SymbolENTO
IPO dateOct 11, 2016
CEOSawyer (Jason)
Company Executives of Entero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Geordan G. Pursglove
Mr. Geordan G. Pursglove
Director
Director
--
--
Mr. Jason Sawyer
Mr. Jason Sawyer
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Jack Syage, Ph.D.
Dr. Jack Syage, Ph.D.
Independent Director
Independent Director
--
--
Mr. Edward Joseph (Ed) Borkowski
Mr. Edward Joseph (Ed) Borkowski
Lead Independent Director
Lead Independent Director
--
--
Mr. Manpreet (Mike) Uppal
Mr. Manpreet (Mike) Uppal
Independent Director
Independent Director
--
--
Ms. Anna Skowron
Ms. Anna Skowron
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Geordan G. Pursglove
Mr. Geordan G. Pursglove
Director
Director
--
--
Mr. Jason Sawyer
Mr. Jason Sawyer
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Jack Syage, Ph.D.
Dr. Jack Syage, Ph.D.
Independent Director
Independent Director
--
--
Mr. Edward Joseph (Ed) Borkowski
Mr. Edward Joseph (Ed) Borkowski
Lead Independent Director
Lead Independent Director
--
--
Mr. Manpreet (Mike) Uppal
Mr. Manpreet (Mike) Uppal
Independent Director
Independent Director
--
--
Ms. Anna Skowron
Ms. Anna Skowron
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Renaissance Technologies LLC
2.57%
Ali (Arif Nasir)
2.29%
The Vanguard Group, Inc.
0.64%
State Street Investment Management (US)
0.58%
Geode Capital Management, L.L.C.
0.38%
Other
93.54%
Shareholders
Shareholders
Proportion
Renaissance Technologies LLC
2.57%
Ali (Arif Nasir)
2.29%
The Vanguard Group, Inc.
0.64%
State Street Investment Management (US)
0.58%
Geode Capital Management, L.L.C.
0.38%
Other
93.54%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.45%
Hedge Fund
2.57%
Investment Advisor/Hedge Fund
0.95%
Investment Advisor
0.65%
Research Firm
0.37%
Other
92.01%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
17
60.75K
5.47%
--
2025Q3
21
60.75K
6.97%
+20.06K
2025Q2
22
41.16K
7.01%
-7.54K
2025Q1
20
48.70K
5.21%
-33.85K
2024Q4
20
25.58K
4.79%
-7.06K
2024Q3
21
32.64K
6.32%
-18.24K
2024Q2
27
49.37K
2.08%
+35.95K
2024Q1
28
13.42K
4.63%
-17.81K
2023Q4
30
27.48K
0.90%
+23.05K
2023Q3
33
4.42K
1.06%
+3.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Renaissance Technologies LLC
4.17K
0.21%
+4.17K
--
Jun 30, 2025
Ali (Arif Nasir)
76.97K
3.82%
+76.97K
--
Jun 06, 2025
The Vanguard Group, Inc.
1.04K
0.05%
-1.00
-0.10%
Aug 31, 2025
Geode Capital Management, L.L.C.
12.19K
0.61%
--
--
Jun 30, 2025
Sapirstein (James E)
12.57K
0.62%
-430.00
-3.31%
Jul 02, 2024
Khosla (Chaitan S)
8.44K
0.42%
+8.30K
+5643.54%
Jun 11, 2024
Borkowski (Edward J)
6.75K
0.34%
--
--
May 15, 2025
Romano (Sarah M.)
6.13K
0.3%
-242.00
-3.79%
Jan 06, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 14, 2025
Merger
3→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Jan 17, 2023
Merger
7→1
Date
Type
Ratio
Aug 14, 2025
Merger
3→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Dec 14, 2023
Merger
20→1
Jan 17, 2023
Merger
7→1
Jan 17, 2023
Merger
7→1
Jan 17, 2023
Merger
7→1
Jan 17, 2023
Merger
7→1
Aug 25, 2022
Merger
30→1
View more
FAQs
Who are the top five shareholders of Entero Therapeutics Inc?
The top five shareholders of Entero Therapeutics Inc are:
Renaissance Technologies LLC holds 4.17K shares, accounting for 0.21% of the total shares.
Ali (Arif Nasir) holds 76.97K shares, accounting for 3.82% of the total shares.
The Vanguard Group, Inc. holds 1.04K shares, accounting for 0.05% of the total shares.
Geode Capital Management, L.L.C. holds 12.19K shares, accounting for 0.61% of the total shares.
Sapirstein (James E) holds 12.57K shares, accounting for 0.62% of the total shares.
Renaissance Technologies LLC holds 4.17K shares, accounting for 0.21% of the total shares.
Ali (Arif Nasir) holds 76.97K shares, accounting for 3.82% of the total shares.
The Vanguard Group, Inc. holds 1.04K shares, accounting for 0.05% of the total shares.
Geode Capital Management, L.L.C. holds 12.19K shares, accounting for 0.61% of the total shares.
Sapirstein (James E) holds 12.57K shares, accounting for 0.62% of the total shares.
What are the top three shareholder types of Entero Therapeutics Inc?
The top three shareholder types of Entero Therapeutics Inc are:
Renaissance Technologies LLC
Ali (Arif Nasir)
The Vanguard Group, Inc.
Renaissance Technologies LLC
Ali (Arif Nasir)
The Vanguard Group, Inc.
How many institutions hold shares of Entero Therapeutics Inc (ENTO)?
As of 2025Q4, 17 institutions hold shares of Entero Therapeutics Inc, with a combined market value of approximately 60.75K, accounting for 5.47% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.51%.
What is the biggest source of revenue for Entero Therapeutics Inc?
In --, the -- business generated the highest revenue for Entero Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
